Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Differential crizotinib response duration among ALK fusion variants in ALK-positive NSCLC

Date

20 Dec 2015

Session

Poster presentation 2

Presenters

TATSUYA Yoshida

Citation

Annals of Oncology (2015) 26 (suppl_9): 125-147. 10.1093/annonc/mdv532

Authors

T. Yoshida1, Y. Oya1, K. Tanaka1, J. Shimizu1, Y. Horio1, T. Hida1, Y. Yatabe2

Author affiliations

  • 1 Department Of Thoracic Oncology, Aichi Cancer Center Hospital, 464–8681 - Nagoya/JP
  • 2 Department Of Pathology And Molecular Diagnosis, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
More

Resources

Aim/Background

ALK rearrangement–positive non-small lung cancers (NSCLC) can be effectively treated with ALK tyrosine kinase inhibitor (TKI) such as crizotinib. However, the magnitude and duration of response was heterogeneous. Several ALK variants have been identified, and there has been few reports focused on the influence of differential ALK variants on the efficacy of crizotinib. Therefore, the aim of this study was to evaluate whether ALK variants show differential efficacy to crizotinib.

Methods

Among 55 patients treated with crizotinib as initial ALK-inhibitor between January 2007 and December 2014, we identified 35 patients whose tumor specimens could be evaluated for ALK variants by reverse transcription polymerase chain reaction. Efficacies of crizotinib such as overall response rate (ORR), progression-free survival (PFS) were retrospectively evaluated according to ALK variants.

Results

In ALK variant status, the most frequent variant was variant 1 in 19 (54%) patients, followed by variant 2 in 5 (14%), variant 3a/3 in 4 (11%), or others in 7 (17%). The ORR was 74 % in all patients, which included 74 % in the variant 1 group and 63% in non-variant 1 group respectively. The median PFS of all patients was 9.7 months. The median PFS was significantly longer in patients with variant 1 than those with non-variant 1 (median of 11.0 months [95% CI, 6.5-43.0 months], vs. 4.2 months [95% CI, 1.6-10.2months], P < 0.05). In multivariate analysis, we identified two significant factors associated with duration of PFS (ALK variant 1: HR 0.4260, 95% CI 0.184-0.984, P < 0.05, and advanced stage: HR 4.3817, 95% CI 1.394-19.583, P < 0.05).

Conclusions

Our data indicated better efficacy of crizotinib in variant 1 than non-variant1. ALK variant status may affect ALK-TKI.

Clinical trial identification

Disclosure

T. Hida: research funding and honoraria from Chugai Pharmaceutical, Pfizer and Novartis. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings